or Try an Advanced Search...

    ETF Components for THNR - Amplify Weight Loss Drug & Treatment ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    LLY F -1.62 14.71
    NVO D -2.79 13.16
    AMGN D -1.09 5.07
    PFE F -0.46 5.03
    TMO D -0.46 4.93
    MRK F -0.05 4.79
    AZN F 0.95 4.62
    WST C 0.76 4.49
    TEVA C 0.45 3.68
    VKTX F -0.25 2.58
    CTLT D 0.05 2.00
    HIMS C 1.31 0.83
    ALT C 2.61 0.27
    OPK B 0.00 0.21
    TERN F -0.89 0.14

    Represented by ETF Holdings

    Keywords: Obesity Pharmaceutical Products S&P 500 Medicine Biopharmaceutical Cancer Asthma Diabetes Inflammation Medication Neuroscience Alzheimer's Disease Animal Health Antibiotics Biotechnology Cholesterol Depressive Disorder Drugs Health Products Hormones
    Industries: Drug Manufacturers - Major Biotechnology Drug Manufacturers - Specialty & Generic Conglomerates Diagnostics & Research Medical Instruments & Supplies

    Recent News for Amplify Weight Loss Drug & Treatment ETF & its Holdings

    Date Stock Title
    Nov 21 AZN We Think AstraZeneca's (LON:AZN) Healthy Earnings Might Be Conservative
    Nov 21 LLY Eli Lilly, Verge announce milestones in ALS collaboration
    Nov 21 AZN 3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
    Nov 21 AZN AstraZeneca upgraded to Neutral from Sell at UBS
    Nov 21 AZN AstraZeneca price target lowered to EUR 140 from EUR 150 at Berenberg
    Nov 21 TEVA Teva Pharmaceutical (TEVA): The Global Leader in Affordable Medicine Under $25
    Nov 21 LLY Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
    Nov 20 LLY Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’
    Nov 20 AMGN AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
    Nov 20 PFE CDC warns of an imminent spike in COVID, flu cases
    Nov 20 MRK Merck Foundation Announces $17 Million U.S. Initiative To Expand Access to High-Quality Cardiac Care
    Nov 20 HIMS Guardant Health Stock Sees RS Rating Jump To 83
    Nov 20 LLY Eli Lilly in pact with Chinese biotech for novel weight loss therapy
    Nov 20 MRK Merck & Co., Inc. (MRK)’s Blockbuster Drugs: A Key Player in Ken Griffin’s Portfolio
    Nov 20 PFE 5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential
    Nov 20 VKTX Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
    Nov 20 HIMS Hims & Hers Health: Far From Dead, Even With Amazon's Threat Ahead
    Nov 20 NVO More companies covering weight loss drugs for their employees
    Nov 20 LLY More companies covering weight loss drugs for their employees
    Nov 20 NVO Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
    The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists (glucagon-like peptide) seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.
    Glucagon Glucagon Like Peptide 1 Peptide Therapeutics
    Back to the Main THNR Page...